Journal Logo

Original Research

An Innovative Model for Naloxone Use Within an OTP Setting: A Prospective Cohort Study

Katzman, Joanna G. MD, MSPH; Takeda, Mikiko Y. PharmD, MS; Bhatt, Snehal R. MD; Moya Balasch, Monica MS; Greenberg, Nina MS; Yonas, Howard MD

Author Information
doi: 10.1097/ADM.0000000000000374
  • Open

Abstract

Drug overdose deaths have nearly tripled in the past 20 years (Rudd et al., 2016) and are now the leading cause of injury death in the United States (US) (Drug Enforcement Administration, 2015). Over 2 million Americans have an opioid use disorder (OUD) (Hedden et al., 2014), and many who use opioids nonmedically switch from prescription opioids to heroin for multiple reasons, including cost and accessibility (Maxwell, 2015). Currently, the rate of nonmedical use of opioid pain relievers in the US for people aged over 11 years is 4.2%, with higher rates for Hispanics (4.9%) and American Indians (6.9%) (Rieckmann et al., 2012).

The US federal agencies along with addiction and pain societies have issued specific guidelines to educate clinicians and key stakeholders regarding safe opioid-prescribing, the need for medication for addiction treatment (MAT), also known as medication-assisted treatment, which has been widely used to treat OUD with medication (eg, methadone, buprenorphine, naltrexone) and behavioral therapy (eg, counseling) and the use of naloxone as a harm reduction measure to save lives (Kampman and Jarvis, 2015; The White House Office of the Press Secretary, 2015; The Academy of Integrative Pain Management, 2017). The Substance Abuse and Mental Health Administration (SAMSHA) and the Centers for Disease Control (CDC) recently issued recommendations for clinicians to consider co-prescribing naloxone to their high-risk patients with OUD and chronic noncancer pain (Substance Abuse and Mental Health Services Administration, 2013; Hedden et al., 2014; Dowell et al., 2016).

As a pure opioid antagonist, naloxone safely reverses the effects of opioid overdose and has been used for decades to resuscitate patients in hospital settings (Kim and Nelson, 2015). Since 1996, naloxone has been an integral harm reduction tool for community-based overdose education and naloxone distribution programs (Galea et al., 2006). In fact, the epidemic of drug overdoses among people who inject drugs (PWID) using heroin is worldwide, and there is growing evidence to support the provision of naloxone to patients with OUD (Darke and Hall, 2003). In the US, opioid overdose is the single greatest cause of mortality among PWID and accounts for more than half of all deaths among people who inject opioids (Latkin et al., 2004).

Many community studies suggest that PWID rarely overdose while alone (Powis et al., 1999; Darke and Hall, 2003) and consistently report a high frequency of witnessing overdose events (Seal et al., 2003; Tracy et al., 2005; Pollini et al., 2006). Moreover, the highest risk for future overdose with PWID seems to be a history of one's own prior overdose (Coffin et al., 2007). PWID also report a reluctance to contact emergency medical services (EMS) upon witnessing an overdose (Seal et al., 2003; Tobin et al., 2005; Tracy et al., 2005; Galea et al., 2006; Strang et al., 2008), and most fatal overdoses occur in private locations such as homes and hotels (Tobin et al., 2005). Qualitative research with PWID indicates that fear of police is a significant barrier to calling EMS during an overdose event (Tracy et al., 2005; Galea et al., 2006). Even when EMS is called to the scene of an opioid overdose, there are significant regional (rural vs urban) differences regarding response times, and overdose reversal outcomes directly correspond to the level of first responder training (Doe-Simkins et al., 2014). Previous community outreach studies with naloxone have shown that opioid overdose education and distribution of naloxone significantly reduces opioid overdose death (Albert et al., 2011; Doe-Simkins et al., 2014).

The primary objective of this prospective cohort study is to measure the number of opioid reversals performed by giving take-home naloxone in this study population. This article is the first large-scale, prospective study to report community benefits of naloxone when provided in an OTP setting.

METHODS

Between April 4, 2016 and July 4, 2016, 244 study participants at the University of New Mexico's Addiction and Substance Abuse Program (UNMASAP) enrolled in this prospective cohort study. The Addiction and Substance Abuse Program is an OTP which specializes in MAT for adults, adolescents, and pregnant women, and treats approximately 600 patients per year. It is the only clinic in New Mexico with the capacity to provide comprehensive treatment to pregnant women with addictive disorders. The Addiction and Substance Abuse Program also receives referrals for all pregnant women on methadone maintenance treatment throughout New Mexico. Currently, 64% of UNMASAP enrollees on MAT are women and 11% are pregnant. This prospective study provided an opportunity to evaluate use of naloxone in a female dominant study cohort. In addition, approximately 80% of patients had previously used intravenous heroin, whereas 20% of patients had primarily used prescription opioid analgesics before beginning MAT at UNMASAP.

This study was registered in the NIH Clinical Trials NCT02669901 on December 21, 2015, and was approved by the University of New Mexico Human Research and Review Committee (a.k.a. IRB) on March 18, 2016 (study ID: #15–616). All human participants gave written informed consent. A Certificate of Confidentiality is on record at the NIH for this study. The inclusion criteria of this study were all patients with an OUD; treated with methadone, buprenorphine, or naltrexone as MAT at the UNMASAP; and aged 18 or older. Exclusion criteria were all patients allergic to naloxone and its inactive ingredients (eg, buffering agents); and younger than 18 years.

Initial Visit

Once the study was approved by the IRB, informational flyers were posted at UNMASAP to inform potential participants. The study coordinator was available during all clinic hours to enroll and educate study participants and their companions (when available) on the signs and symptoms of opioid overdose; appropriate response during an overdose (calling 911, rescue breathing, and remaining with the person until EMS arrives); and how to use the naloxone auto-injector (Kaleo Inc., 2014). Participants in this study were encouraged, but not required, to bring a companion to the initial visit. If the study participant did not bring a companion, he/she was highly encouraged to educate his/her closest friend/relative in how to use naloxone in case of overdose. Companion attendance at the initial visit was recorded.

Naloxone was distributed at the initial visit. The study coordinator spent about 15 to 20 minutes with each participant in a private treatment room at UNMASAP obtaining baseline information which included demographics, social history, medical history, and history of illicit drug use. Education on opioid overdose and rescue breathing was also provided during this time. At the end of the visit, 1 naloxone auto-injector kit (2 naloxone auto-injectors and 1 training auto-injector per kit) was given to each study participant. The research coordinator demonstrated naloxone kit use to the participant until he/she reported self-efficacy and performed proper kit use.

Follow-up Visit

Every study participant was asked to follow up at 3 months regardless of whether or not their naloxone kit was used. Of 244 participants, 215 participants completed a 3-month follow-up visit and additional visit(s) if/when a naloxone auto-injector replacement kit was needed. At each follow-up/replacement visit, the study coordinator conducted a short interview to ascertain if and why a replacement kit was needed (lost, stolen, or overdose [OD]). If the participant used the kit for opioid overdose, then more detailed information was collected, such as number of naloxone doses used in the event of an OD, details of the clinical outcome of the person overdosing (ie, successful overdose reversal, death, and utilization of healthcare institution [eg, EMS, emergency room, hospitalization]), relationship to the person rescued (family, friend, stranger), causality (ie, type[s] of opioid), and whether or not 911 was called after utilization of the naloxone auto-injector kit. The observation period ended after the enrollee's 3-month follow-up visit.

Statistical Analysis

Statistical analysis was performed using Stata Version 12 (College Station, TX). The research team (MM, MYT, NG) collected the data and used a descriptive analysis for demographic, social status, education, and past overdose history. Significant differences in the UNMASAP and the study population were tested using chi-square analysis.

RESULTS

Between April 4, 2016 and July 4, 2016, 244 study participants were enrolled into this study. The observation period continued for 3 months for each study participant. During this time, 31 study participants reported overdose reversals using their naloxone auto-injector kits on 38 community members. This demonstrates that 13% of the study participants used the take-home naloxone to perform an overdose reversal in the community. Figure 1 shows the summary of the recruitment status and overdose reports from the participants. All reported overdose reversals were successful, and all involved PWID with heroin. Of these reported overdose reversals, 50% (n = 19) required 1 dose of naloxone, 45% (n = 17) required 2 doses of naloxone, and 5% (n = 2) required 3 doses of naloxone. For the 2 overdose reversals requiring 3 doses of naloxone, the third naloxone dose was delivered by EMS for 1 individual, whereas the second individual received a third dose from a study participant who had an extra naloxone dose available. Among 31 study participants who reported opioid overdose reversals, 21 participants were female (67.7%) and 10 were male (32.3%).

FIGURE 1
FIGURE 1:
Study design and results.

Emergency medical services were called 48% of the time for these 38 reported overdose reversals. Only 1 study participant overdosed during this study period, and she was rescued with naloxone by EMS. This same study participant also reported using naloxone for an overdose reversal with a community member.

The most common reasons for study participants “lost to follow-up” were relocation and discontinuation with MAT at UNMASAP. Except for the patients who were discharged from UNMASAP due to behavioral reasons, all study participants “lost to follow-up” were called by the research coordinator on the telephone in an attempt to have them rejoin the study.

Demographics

Table 1 shows distributions of sex, race, age, opioid replacement therapy, and companion attendance for study participants.

TABLE 1
TABLE 1:
Demographics and Medication Treatment

The cohort of 244 study participants included 174 females (71%) and 70 males (29%). There was no statistically significant difference in the UNMASAP clinic sex distribution, which had 65% females and 35% males (P = 0.108) on September 2, 2016. The UNMASAP clinic gives priority access to pregnant women and mothers with newborns.

At the initial study intake, 44% (n = 108) of the study participants stated that they had personally overdosed at least once in their life, whereas 87% (n = 200) had witnessed someone else overdose at least once in their life.

Type of Medication Treatment

Of the 244 study participants, 80% (n = 193) were prescribed methadone, 17% were prescribed buprenorphine (n = 42), and 3% (n = 6) were prescribed naltrexone, in addition to participating in their regular behavioral therapy programs.

Overdose Education, Take-home Naloxone, and Reported Overdose Reversals

Ten per cent (n = 25) of study participants brought a companion with them to the initial visit of opioid overdose education and take-home naloxone distribution, whereas most study participants (90%, n = 219) did not have a companion with them during the initial visit. Four study participants who brought a companion to the overdose education also performed an overdose reversal in the community.

Of the 31 study participants who performed overdose reversals on community members, 27 study participants reported 1 reversal, 2 reported 2 reversals, 1 reported 3 reversals, and 1 reported 4 reversals. Out of the 38 overdose reversals, 87% were known by the study participants (acquaintance, friend, family member, significant other), whereas 13% were strangers to the study participants (Table 2).

TABLE 2
TABLE 2:
Relationship of Study Participant Who Performed Overdose Reversal on Community Member

DISCUSSION

Study Participants as Bystanders

All study participants were trained in drug overdose recognition and in use of the naloxone auto-injector. The initial intake took approximately 15 to 20 minutes, which is consistent with the minimal training needed in other studies (Behar et al., 2015; Takeda et al., 2016). Only 10% of study participants brought a close family member or friend to the initial visit for naloxone training. This small percentage of companions present during the initial visit was not unexpected since most patients travel alone to UNMASAP for their regular visits. The 1 study participant who experienced an overdose did not have a companion at her initial visit and was rescued by EMS. Each of the 31 study participants (including the 1 study participant who overdosed herself) acted in the capacity of a “bystander” as they performed overdose reversals on 38 community members. A bystander is a person who may have received training on identifying opioid overdose, but is able to perform rescue breathing and can administer naloxone (Walley et al., 2013). In this study, 21 of 31 participants reporting reversals were females, which closely resembles the percentage of female study participants enrolled. This study demonstrates that females are quite capable of acting as a bystander and performing overdose reversals with naloxone.

These results are consistent with existing literature demonstrating that people with OUD are willing to administer naloxone during an overdose if the medication is made directly available to them (Seal et al., 2003; Galea et al., 2006; Strang et al., 2008; Clark et al., 2014). This validates the concept that the recipient of naloxone is usually not the patient for whom the naloxone has been given or prescribed. Instead, the naloxone is most often used on someone else. Training of the patient who is given naloxone builds the capacity to respond in a timely and effective manner to reverse overdose in another individual (Strang et al., 2008).

The rate of overdose reversal in this study population was high and may relate to study participants acting as bystanders for community members at high risk for opioid overdose. For every 100 study participants enrolled, approximately 16 overdose reversals were performed on community members by the enrollees themselves. Our data confirm that a high percentage of participants in this study have either witnessed (87%) an overdose event or have been rescued (44%) by naloxone previously. Naloxone is used frequently by those who inject heroin, and this familiarity can increase the chance for overdose reversals performed (Sherman et al., 2007; Des Jarlais et al., 2009). Perhaps, the study participants in our cohort who have acted as a bystander and performed overdose reversal(s) are unique in their capacity to help others. It is possible that these individuals can eventually serve a role in the community as peer educators.

Should Mandatory Take-home Naloxone Distribution be Required in Federally Qualified Opioid Treatment Programs (OTPs)?

Although the SAMSHA opioid tool kit suggests prescribing naloxone to patients who have a history of opioid substance use disorder, this remains a recommendation to providers and patients, and not a requirement (Substance Abuse and Mental Health Services Administration, 2013). The recent CDC guidelines, published for pain management, also suggest, but do not require, co-prescribing naloxone for those patients with a substance use disorder, history of overdose or taking a high opioid dosage, which they specify as 50 morphine milligram equivalents per day (Dowell et al., 2016). Patients treated in methadone maintenance treatment centers during the induction period remain at high risk for opioid overdose (Kimber et al., 2015).

We have also seen in our study that the participants perform opioid overdose reversal(s) in their community quite readily. Historical medication data from UNMASAP has revealed that less than 10% of our cohort was prescribed naloxone during the 2 years before study enrollment. It is the authors’ contention that take-home naloxone combined with opioid overdose education is critically important to continuing the success of the overdose reversals performed in this environment. A written prescription for naloxone may not have the same impact.

Limitations

Because of the Health Insurance Portability and Accountability Act, direct outcome assessment of the community members who were treated with naloxone for an overdose reversal was not possible. It is impossible to know which community members would have survived without the naloxone provided to them. Many people survive overdose from heroin and prescription opioid pain relievers without naloxone or EMS support.

CONCLUSIONS

This prospective study demonstrates that there are a significant number of overdose reversals reported in the community by study participants in an OTP setting who received opioid overdose education and were given take-home naloxone. In this study, naloxone is not commonly used on the index study participant, but is most often used on a secondary target among PWID. It appears that social contacts are a critical harm reduction component to the overdose reversals seen within the community associated with PWID. It is the authors’ contention that take-home naloxone should be considered a necessary component of any federally qualified OTP program. The authors anticipate that future naloxone investigation may focus on the identification of specific characteristics of study participants performing overdose reversals compared with the study participants who did not use the naloxone. Additionally, the authors hope to perform qualitative ethnographic interviews on study participants who did and did not perform overdose reversal(s) in the community.

Acknowledgments

The authors wish to thank Ann Alderete, RN, Amal Alchibli, MD, Chamron Martin, Ed Nemoto, PhD, and Kim Page, PhD, for their assistance with this study.

REFERENCES

Albert S, Brason FW, Sanford CK, et al. Project Lazarus: community-based overdose prevention in rural North Carolina. Pain Med 2011; 12 (Suppl 2):S77–S85.
Behar E, Santos GM, Wheeler E, et al. Brief overdose education is sufficient for naloxone distribution to opioid users. Drug Alcohol Depend 2015; 148:209–212.
Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med 2014; 8:153–163.
Coffin PO, Tracy M, Bucciarelli A, et al. Identifying injection drug users at risk of nonfatal overdose. Acad Emerg Med 2007; 14:616–623.
Darke S, Hall W. Heroin overdose: research and evidence-based intervention. J Urban Health 2003; 80:189–200.
Des Jarlais DC, McKnight C, Goldblatt C, et al. Doing harm reduction better: syringe exchange in the United States. Addiction 2009; 104:1441–1446.
Doe-Simkins M, Quinn E, Xuan Z, et al. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health 2014; 14:297.
Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain: United States, 2016. MMWR Recomm Rep 2016; 65:1–49.
Drug Enforcement Administration. 2015 National Drug Threat Assessment Summary. Available at: https://www.dea.gov/docs/2015%20NDTA%20Report.pdf. Accessed April 26, 2017.
Galea S, Worthington N, Piper TM, et al. Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City. Addict Behav 2006; 31:907–912.
Hedden S, Kennet J, Lipari R, et al. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. In: Substance Abuse and Mental Health Services Administration, ed. SAMHSA; 2014:1–64.
Kaleo Inc. EVZIO (naloxone hydrochloride injection) Auto-Injector for Intramuscular or Subcutaneous Use. In: Richmond VA, ed. Kaleo Inc., 2014:1–12.
Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med 2015; 9:358–367.
Kim HK, Nelson LS. Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Opin Drug Saf 2015; 14:1137–1146.
Kimber J, Larney S, Hickman M, et al. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychiatry 2015; 2:901–908.
Latkin CA, Hua W, Tobin K. Social network correlates of self-reported non-fatal overdose. Drug Alcohol Depend 2004; 73:61–67.
Maxwell J. The pain reliever and heroin epidemic in the United States: shifting winds in the perfect storm. J Addict Dis 2015; 34:127–140.
Pollini RA, McCall L, Mehta SH, et al. Response to overdose among injection drug users. Am J Prev Med 2006; 31:261–264.
Powis B, Strang J, Griffiths P, et al. Self-reported overdose among injecting drug users in London: extent and nature of the problem. Addiction 1999; 94:471–478.
Rieckmann T, McCarty D, Kovas A, et al. American Indians with substance use disorders: treatment needs and comorbid conditions. Am J Drug Alcohol Abuse 2012; 38:498–504.
Rudd R, Seth P, David F, et al. Increases in drug and opioid-involved overdose deaths: United States, 2010–2015. MMWR Morb Mortality Wkly Rep 2016; 65:1445–1452.
Seal KH, Downing M, Kral AH, et al. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area. J Urban Health 2003; 80:291–301.
Sherman SG, Cheng Y, Kral AH. Prevalence and correlates of opiate overdose among young injection drug users in a large U.S. city. Drug Alcohol Depend 2007; 88:182–187.
Strang J, Manning V, Mayet S, et al. Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Addiction 2008; 103:1648–1657.
Substance Abuse and Mental Health Services Administration. SAMHSA Opioid Overdose Prevention Toolkit. In: SAMHSA, ed. Rockville, MD: HHS Publication; 2013.
Takeda MY, Katzman JG, Dole E, et al. Co-prescription of naloxone as a Universal Precautions model for patients on chronic opioid therapy-Observational study. Subst Abus 2016; 37:591–596.
The Academy of Integrative Pain Management. Co-Prescribing of Naloxone in Conjunction With Opioid Therapy. Available at: http://blog.aapainmanage.org/co-prescribing-of-naloxone-in-conjunction-with-opioid-therapy/. Accessed April 23, 2017.
The White House Office of the Press Secretary. FACT SHEET: Obama Administration Announces Public and Private Sector Efforts to Address Prescription Drug Abuse and Heroin Use; October 21, 2015. Available at: https://www.whitehouse.gov/the-press-office/2015/10/21/fact-sheet-obama-administration-announces-public-and-private-sector. Accessed December 2, 2016.
Tobin KE, Davey MA, Latkin CA. Calling emergency medical services during drug overdose: an examination of individual, social and setting correlates. Addiction 2005; 100:397–404.
Tracy M, Piper TM, Ompad D, et al. Circumstances of witnessed drug overdose in New York City: implications for intervention. Drug Alcohol Depend 2005; 79:181–190.
Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013; 346:f174.
Keywords:

addiction; harm reduction; naloxone; opioid use disorder; overdose deaths

Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Addiction Medicine.